01893nam a2200397 i 4500001001300000003000600013005001700019007001400036008004100050040002800091042000800119043001200127050002000139074001600159086002700175110007100202245019200273264006000465300002900525336002600554337002700580338003100607490002300638500010800661500003600769500002500805504004100830533010400871650001400975650005300989650005401042655003301096776015301129776015301282810006001435on1023035134OCoLC20180312141844.0he bmb024bbca180214s2017    dcu     bb   f000 0 eng c  aGPObengerdacGPOdMvI  apcc  an-us--- 4aKF26b.F5 2016t  a1038-B (MF)0 aY 4.F 49:S.HRG.114-6661 aUnited States.bCongress.bSenate.bCommittee on Finance,eauthor.10aExamining the proposed Medicare part B drug demonstration :bhearing before the Committee on Finance, United States Senate, One Hundred Fourteenth Congress, second session, June 28, 2016. 1aWashington :bU.S. Government Publishing Office,c2017.  aiii, 100 pages ;c24 cm.  atextbtxt2rdacontent  amicroformbh2rdamedia  amicrofichebhe2rdacarrier1 aS. hrg. ;v114-666  aPaper version available for sale by the Superintendent of Documents, U.S. Government Publishing Office.  aShipping list no.: 2017-0194-M.  aCRDP Program record.  aIncludes bibliographical references.  aMicrofiche.b[Washington, D.C.] :cU.S. Government Printing Office,d[2017]emicrofiche : negative. 0aMedicare. 0aDrugsxPricesxGovernment policyzUnited States. 0aPharmaceutical services insurancezUnited States. 7aLegislative hearings.2lcgft08iPrint version:aUnited States. Congress. Senate. Committee on Finance.tExamining the proposed Medicare part B drug demonstrationw(OCoLC)100206583508iOnline version:aUnited States. Congress. Senate. Committee on Finance.tExamining the proposed Medicare part B drug demonstrationw(OCoLC)9958537471 aUnited States.bCongress.bSenate.tS. hrg. ;v114-666.